About Dr. Ding Guoping
Biography
Dr. Ding Guoping is a Chief Physician and PhD at the General Surgery Department of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine. He has pioneered micro-incision laparoscopic cholecystectomy and specializes in the comprehensive treatment of hepatobiliary and pancreatic tumors.
Professional Experience
Dr. Ding has been practicing since 2005. He served at Ningbo No.2 Hospital and the Second Affiliated Hospital of Zhejiang University before joining Sir Run Run Shaw Hospital in 2014. He has rich clinical experience in minimally invasive treatment of gallstones and advanced pancreatic cancer management.
Medical Innovation
"Pioneered micro-incision laparoscopic cholecystectomy, shortening the surgery time to less than 20 minutes, performing over 600 such procedures annually."
Research Projects
Led and participated in multiple national and provincial research projects, including studies on RFXAP gene silencing in pancreatic cancer metastasis and exosome-based therapies.
Key Research Grants
Molecular Mechanisms and Applications of RFXAP Inhibition in Pancreatic Cancer Invasion and Metastasis
Co-expression Network Analysis of RFXAP Protein in Pancreatic Cancer and Its Clinical Significance
Role and Mechanism of RFXAP Gene Silencing Induced by Pancreatic Cancer Exosomes in Early Metastatic Events
Experimental Study on DC/CIK Cell Induction Based on Exosomes and Its Therapeutic Effects in Pancreatic Cancer
Construction of a Biotherapeutic Model for Pancreatic Cancer and Study of Changes in Circulating Exosomal microRNA Expression Profiles
Regulatory Mechanisms of microRNA in DC Differentiation Induced by Pancreatic Cancer and DC-SIGN Expression
Professional Societies
Committee Member, Pancreatic Diseases, Chinese Research Hospital Association
Secretary-General & Standing Committee Member, Biliary Tumor, Zhejiang Anti-Cancer Association
Committee Member, Evidence-Based Medicine Group, Abdominal Tumor, CMEA
Key Publications
Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. Oncotarget. 2015
A modified Jarnagin-Blumgart classification better predicts survival for resectable hilar cholangiocarcinoma. World J Surg Oncol. 2015
Assessment of 188Re marked anti MHC class II antibody by PBMC stimulated by donor alloantigen. Chin Med J. 2011
Saline conducted electric coagulation (SCEC): original experience in experimental hepatectomy. J Zhejiang Univ Sci B. 2012